SCORE2 Comparative Trial

Grants and Contracts Details

Description

The Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) will assess whether one of the most commonly used anti-VEGF drgus, bevacizumab, is non-inferior to a second generation anti-VEGF drug, aflibercept, for the treatment of macular edema secondary to Central Retinal Vein Occlusion. Rescue therapy, in cases where intial therapy is not successful, will be evaluated.
StatusFinished
Effective start/end date9/30/133/31/19

Funding

  • Pennsylvania State University: $19,494.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.